Amgen Drug Reduces Cardiovascular Death Risk, Aids Psoriasis Market

Amgen Inc. is highlighting recent findings concerning its cardiovascular drug, Repatha. Coverage today indicates that Repatha has been shown to reduce the risk of death in patients who are at high risk for a first heart attack or stroke. This finding positions the drug as a significant tool in managing serious cardiovascular events.

The drug, described as one of Amgen's major revenue generators, has reportedly cut the risk of dying by approximately 20% for the studied patient group. These developments underscore the therapeutic importance of Repatha in preventing mortality among individuals with elevated cardiovascular risk factors.

In separate market news, Amgen has been identified as a significant entity within the palmoplantar pustulosis (PPP) market. A newly available market report profiles the company alongside other major pharmaceutical firms. The report segments the PPP market by treatment type and distribution channels, suggesting a competitive landscape for therapies addressing this condition.

While not directly detailing Amgen's involvement, other market analyses released today cover broader therapeutic areas such as non-melanoma skin cancer, indicating continued research and development across various disease indications and treatment modalities within the pharmaceutical industry.